Case Study: Expanding Availability of Healthcare Services
Differential Pricing to Address Affordability in Egypt, Roche
Egypt has one of the highest burdens of hepatitis C virus (HCV) infection in the world. Affordability of treatment is a significant problem. In 2007, Roche partnered with the government to establish a national project for treating chronic hepatitis C. Part of the project included introducing Pegferon, a second brand of our hepatitis treatment, Pegasys, which is the same medicine but is packaged locally, using local manufacturers. This approach allowed us to introduce differential pricing within Egypt, with Pegferon available to the government at a significantly reduced price.
We complement this offer with products for diagnosis and treatment monitoring, helping to maximize medical services and patient benefits.
Introduction of a second brand has enabled us to offer differential pricing to governments to help them provide public reimbursement, with minimal diversion to other markets.
By working with governments, local manufacturers, and distributors, we can share our manufacturing techniques and supply chain management practices through skills training and technology transfer. This way of working helps build or expand local infrastructure, increases expertise, provides employment, and strengthens relationships with key stakeholders.
This pilot has become a model that we are introducing in other countries and disease areas where permitted by local regulatory and legal requirements.
Results to Date?
The second brand, Pegferon, has increased access to treatment all over the country. Since the project launched in 2007, more than 160,000 patients have been treated with it who otherwise may not have received treatment.
Use of Pegferon has also increased confidence in Pegasys, leading to its increased usage in the private-payer market.
Additionally, this work helped strengthen our relationship with the Ministry of Health, and with both public and medical societies.
Related Case Studies on Expanding Availability of Healthcare Services
- StarBem, Sanofi
- Differential Pricing to Address Affordability in Egypt, Roche
- Arogya Parivar (Hindi for “Healthy Family”), Novartis
- NGO Narmada Samagra’s River Ambulance and Water Testing Project, Merck Serono
- Janssen eMedical Advisor (JeMA) Platform for Sub-Saharan Africa, Janssen, the Pharmaceutical Companies of Johnson & Johnson
- Janssen Global Public Health HIV Medicines Access & Partnerships Program, Janssen, the Pharmaceutical Companies of Johnson & Johnson
- Bristol-Myers Squibb Agreement with Medicines Patent Pool to Increase Access to Atazanavir, Bristol-Myers Squibb
- Base of the Pyramid Innovation Project, Novo Nordisk
- Differential Pricing Policy for Least Developed Countries, Novo Nordisk
- Private Health Insurance for Cancer Treatment in China, Roche
- Janssen Global Access and Partnership Program (GAPP), Janssen, the Pharmaceutical Companies of Johnson & Johnson
- New Business Models to Increase Access in Developing Countries, GlaxoSmithKline
- Alcance, Sanofi
- SMS for Life, Novartis International AG